Publication Name	World Journal of Clinical Oncology
Manuscript ID	9253
Country	United States

Received	2014-01-29 20:45
Peer-Review Started	2014-01-29 21:55
To Make the First Decision	2014-03-12 17:00
Return for Revision	2014-03-19 13:48
Revised	2014-03-21 05:18
Second Decision	2014-05-16 17:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-05-16 17:51
Articles in Press	2014-05-23 09:08
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-24 14:19
Publish the Manuscript Online	2014-12-11 14:23

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Genomic era diagnosis and management of hereditary and sporadic colon cancer
Manuscript Source	Invited Manuscript
All Author List	Edward David Esplin and Michael Paul Snyder
Funding Agency and Grant Number	Funding Agency Grant Number Child Health Research Institute and the Stanford CTSA UL1 TR000093
Corresponding Author	Edward D. Esplin, M.D., Ph.D. Clinical Scholar Tashia and John Morgridge Endowed Fellow Snyder Lab Department of Genetics Stanford University Medical Center 300 Pasteur Drive, Alway M302 Stanford, CA 94305 USA Phone: 650-723-9914 Fax: 650-725-1534
Key Words	Colorectal adenocarcinoma; Familial adenomatous polyposis; Genome sequencing; Personalized medicine; Cancer genomics; Pharmacogenomics; Genomic medicine
Core Tip	The era of genomic sequencing is beginning to make significant impact on the diagnosis and management of sporadic and inherited colorectal adenocarcinoma (CRC) such as familial adenomatous polyposis. This review will discuss the current guidelines for diagnosis and management of CRC and how genomic sequencing is enabling earlier definitive diagnosis with associated intensive surveillance and preventative interventions, molecular tumor characterization directing tumor specific therapy, germline patient genome analysis which informs individual drug tolerance and efficacy, and is evolving to develop post-treatment surveillance, with the potential to ultimately decrease the current prevalence and mortality of CRC, sporadic and hereditary.
Publish Date	2014-12-11 14:23
Citation	Esplin ED, Snyder MP. Genomic era diagnosis and management of hereditary and sporadic colon cancer. World J Clin Oncol 2014; 5(5): 1036-1047
URL	http://www.wjgnet.com/2218-4333/full/v5/i5/1036.htm
DOI	http://dx.doi.org/10.5306/wjco.v5.i5.1036

Full Article (PDF)	WJCO-5-1036.pdf
Full Article (Word)	WJCO-5-1036.doc
Manuscript File	9253-Review.docx
Answering Reviewers	9253-Answering reviewers.pdf
Copyright License Agreement	9253-Copyright assignment.pdf
Peer-review Report	9253-Peer review(s).pdf
Scientific Editor Work List	9253-Scientific editor work list.pdf